CXCR3 and pulmonary fibrosis: CXCL10 was released along with pro-inflammatory mechanisms that promoted pulmonary fibrosis in COVID-19 patients through the CXCL10-CXCR3 signaling system and CXCL10 was identified with a poor prognosis in COVID-19 patients (35, 36).